Drug intelligence / Profile preview

Shenkefu Capsule

Development stage: Unknown
Lead developer: Yunnan Shengke Pharmaceutical
Administration: Oral

Overview

Shenkefu Capsule is a Traditional Chinese Medicine (TCM) oral formulation developed by Yunnan Shengke Pharmaceutical, a subsidiary of the Good Doctor Pharmaceutical Group. It is indicated for the treatment of kidney disease, specifically targeting renal repair and restoration. As a TCM herbal preparation, it consists of multiple botanical ingredients intended to work synergistically, though its specific molecular targets and mechanism of action are not publicly defined. The candidate is currently in Phase 1/2 clinical development in China.

Brand names: Shenkefu Capsule肾可复胶囊
Other names: ShenkefuShenkefu 胶囊

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on Shenkefu Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenkefu Capsule.

Explore the full profile